Urgent.ly stock jumps again in premarket as ULY extends a volatile run
31 December 2025
1 min read

Urgent.ly stock jumps again in premarket as ULY extends a volatile run

NEW YORK, December 31, 2025, 04:26 ET — Premarket

  • Urgent.ly (ULY) was up about 27% in premarket trade after a 52% jump in Tuesday’s regular session. StockAnalysis
  • The microcap’s latest disclosed update was an SEC filing saying its annual meeting was adjourned for lack of quorum and will reconvene on Jan. 28. SEC
  • Heavy volume on Tuesday far exceeded the stock’s typical trading activity, a setup that can amplify price swings. Finviz

Shares of Urgent.ly Inc surged 26.8% to $3.50 in premarket trading on Wednesday, after the roadside-assistance software provider ended Tuesday up 52.5% at $2.76. StockAnalysis

The outsized move is drawing attention to Urgent.ly’s thin trading profile and a recent corporate update that reset the clock on a key shareholder vote. That matters now because microcap stocks can gap sharply when order flow concentrates ahead of scheduled events. Finviz

Urgent.ly said in a Form 8-K — a filing used to disclose major corporate events — that it convened and then adjourned its 2025 annual meeting “due to insufficient votes to constitute a quorum.” A quorum is the minimum shareholder participation required to conduct business. SEC

In that filing, signed by Chief Executive Officer Matthew Booth, the company said: “The Annual Meeting will reconvene at 11:00 a.m., Eastern Time, on Wednesday, January 28, 2026.” SEC

Tuesday’s rally came on unusually heavy turnover. Urgent.ly has about 2.19 million shares outstanding and a float of roughly 1.95 million shares, according to market data, and it traded more than 8.3 million shares in the regular session — about 20 times its average volume. Finviz

Beyond the meeting update, there was no new earnings release or product announcement in the latest filing, and the company did not disclose changes to the proposals to be voted on. SEC

Urgent.ly operates a mobility assistance platform that connects drivers with service providers for roadside help and related services across automotive and insurance channels, according to its company profile. StockAnalysis

The price action has been abrupt even by small-cap standards. On Tuesday, ULY opened around $1.87 and traded as high as $3.09 before settling at $2.76, StockAnalysis data showed. StockAnalysis

The stock is still well below its 52-week high of $17.99, and it has traded as low as $1.74 in the past year, underscoring how quickly sentiment has shifted around the name. Finviz

For traders, the near-term question is whether Wednesday’s premarket gains hold into the regular session, or fade as liquidity deepens after the open. With a small float, even modest buying or selling can move the price disproportionately. Finviz

Investors will also watch for any follow-up disclosures ahead of the rescheduled annual meeting, including whether the company can secure sufficient votes to reach a quorum when the meeting reconvenes. SEC

Stock Market Today

  • 3LAM.PA stock surges 11.30% pre-market on EURONEXT amid AMD momentum
    January 20, 2026, 9:39 PM EST. GraniteShares 3x Long AMD Daily (3LAM.PA) climbed 11.30% to €0.22 in early trading on EURONEXT on Jan 21, 2026, driven by short-term momentum and linked to Advanced Micro Devices (AMD) moves. The 3x leveraged exchange-traded product (ETP) magnifies AMD price swings, causing high volatility and wider intraday ranges. Despite volume at 367,263 shares being below 50-day average liquidity, technical indicators show oversold conditions and a strong trend, supporting a potential short bounce. Meyka AI assigned a 'Hold' rating with a medium-term price target of €0.40, signaling a 79% upside. Traders should heed risks from leverage, daily reset decay, and limited liquidity, favoring short-term strategies with cautious position sizing.
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades
Previous Story

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Profusa stock whipsaws: PFSA dips premarket after 78% surge on debt restructuring
Next Story

Profusa stock whipsaws: PFSA dips premarket after 78% surge on debt restructuring

Go toTop